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Abstract
Tumor microenvironmental stresses, such as hypoxia and lactic acidosis, play important roles in tumor progression.
Although gene signatures reflecting the influence of these stresses are powerful approaches to link expression with
phenotypes, they do not fully reflect the complexity of human cancers. Here, we describe the use of latent factor models to
further dissect the stress gene signatures in a breast cancer expression dataset. The genes in these latent factors are
coordinately expressed in tumors and depict distinct, interacting components of the biological processes. The genes in
several latent factors are highly enriched in chromosomal locations. When these factors are analyzed in independent
datasets with gene expression and array CGH data, the expression values of these factors are highly correlated with copy
number alterations (CNAs) of the corresponding BAC clones in both the cell lines and tumors. Therefore, variation in the
expression of these pathway-associated factors is at least partially caused by variation in gene dosage and CNAs among
breast cancers. We have also found the expression of two latent factors without any chromosomal enrichment is highly
associated with 12q CNA, likely an instance of ‘‘trans’’-variations in which CNA leads to the variations in gene expression
outside of the CNA region. In addition, we have found that factor 26 (1q CNA) is negatively correlated with HIF-1a protein
and hypoxia pathways in breast tumors and cell lines. This agrees with, and for the first time links, known good prognosis
associated with both a low hypoxia signature and the presence of CNA in this region. Taken together, these results suggest
the possibility that tumor segmental aneuploidy makes significant contributions to variation in the lactic acidosis/hypoxia
gene signatures in human cancers and demonstrate that latent factor analysis is a powerful means to uncover such a
linkage.
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Introduction
The promise and challenge of cancer genomics
Human cancers are extremely heterogeneous due to multiple
mutations in oncogenes and tumor suppressor genes, varying
environmental conditions, and a huge range of germline and
somatic variations. While the individual effects of a genetic
alteration or environmental factors may be quite subtle, their
combined effects lead to immense natural heterogeneity in tumor
phenotypes, disease outcomes, and response to therapies. The use
of microarrays to capture global gene expression patterns in
human cancers has lead to an explosion of knowledge regarding
the genetic basis of cancer heterogeneity. Experiments that have
previously been performed one gene at a time can now be done on
the entire complement of transcribed genes. However, this leads to
a tremendous challenge of divining meaning behind the vast
amounts of biological data and turning it into hypotheses and new
understanding of the biology behind tumor heterogeneity.
Gene signature approaches for cancer gene expression
In relating tumor gene expression data to tumor heterogeneity,
one powerful approach is the use of gene signatures to dissecting
the complexity of cancer genomic data. These gene signatures
represent a set of genes which are coordinately regulated in
particular biological processes and specific perturbations, first
determined based in cultured cells or other supervised analysis to
represent particular biological processes and [1–8]. The expression
signatures are portable and can be assayed in varied contexts, and
so provide the capacity to link otherwise heterologous systems to
provide a mechanism to link the defined biological processes with
the complex phenotypes of human tumors. These signatures can
then be used to recognize similar molecular features in human
cancer samples in vivo and interrogate the relevance of particular
biological processes and perturbations in human cancer and
evaluate their relationship with other clinical and molecular
features.
There are many different means to quantitatively define
signature activities in human tumor gene expression datasets.
One approach involves extracting the genes in a signature defined
in an experimental setting and examining their co-variation in
other datasets. These genes can then be used to reclassify tumors
based on clustering of the expression of the genes in a pathway
[2,3]. Another approach ignores signatures and simply seeks to
collect genes that demonstrate high levels of correlation across
samples into gene modules. Classification and prediction tasks are
then performed on the expression of modules rather than
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annotation of human tumors [9]. It is also possible to use Bayesian
statistics to determine the probability of the pathway activities to
avoid the instability of hierarchical clustering [4,10]. Gene set
enrichment analysis (GSEA) seeks to compare observed expression
patterns to pre-defined, curated pathways [11]. Finally, the
connectivity map [12] uses a similar approach to establish
connections with perturbations due to the presence of drugs and
other small molecules. We have also used these and similar
approaches to show that wound healing [2], vascular injury
responses [13] and various oncogenic mutations [4,10,14–17] can
play important roles in tumor progression.
Poorly dissected complex structures of gene signatures
in vivo
Although this projection of various gene signatures onto
heterologous gene expression data of human cancer in vivo has
been quite successful, there are also significant limitations. The
gene signatures which have been defined in vitro using cultured
cells simply cannot fully reflect the complexity of variation seen in
human cancers. This discrepancy can be due to many reasons. For
example, there may be several components of pathway signaling
observed in vitro, but which are subject to multiple regulatory
controls that break down the clear patterns in vivo. Some genes
may be better representatives of pathway activity in vivo because
they are less likely to be involved in other pathways, or because
they react to environmental conditions that are not present in vitro;
others present in the experimental signature may be unexpressed
in vivo. For example, it is known that Ras has at least three major
downstream pathways - Ral, Raf and PI3K. The activation and
role of each pathway may be different under oncogenic
transformation and tumor maintenance [18,19]. Furthermore,
cancer cell genomes have many amplifications, deletions and point
mutations (copy number alterations (CNAs) or aneuploidies), any
subset of which may modulate the pathway activity of both
oncogenic signaling and microenvironmental responses. Since
only normal or cloned cell lines are used to generate in vitro
signatures, the consequences of these complex DNA alterations in
tumors are not observed. Compositions of cell types in tumors also
reflect the continuous evolution and selection of cells fittest to
survive under harsh tumor microenvironmental stresses, possibly
over years of development. In addition, human cancers also
involve heterogeneous cell types with complex intercellular
interactions as well as temporal and spatial variation in expression.
These factors cannot be easily modeled in vitro using cell culture or
captured using microarrays.
Factor analysis to uncover in vivo complexity of original
gene signatures
Our approach to address the limitations of the gene signatures is
to apply statistical latent factor models using in vivo cancer data to
further dissect the in vitro derived ‘‘primary signatures’’ into
components which better represent the complexity and structure
captured by the global gene expression of human cancers in vivo.
Statistical analysis using latent factor models aims to address this
by identifying and estimating potentially many factors in the in
vivo expression patterns of sets of signature genes defined in vitro;
these factors or ‘‘sub-signatures’’ retain their relationship to the
original signature but represent distinct, interacting components of
the biological processes the initial signature. This approach has
been successfully applied to generate an elaborated picture of the
complexity of patterns of variation shown by the signature gene
set, and additional genes apparently related to the gene set, in
observational contexts [14,20–26]. Elaborating the factor profile
underlying the original signature can improve the in vivo
relevance by more fully describing the diversity of in vivo
expression patterns, and may enhance prognostic value and
provide mechanistic insights into how biological processes affect
clinical phenotypes.
Gene signature of tumor microenvironmental stresses
The tumor microenvironment is characterized by many
chemical stresses, such as oxygen depletion (hypoxia), high lactate
and extracellular acidosis (lactic acidosis) [27]. Given the
importance of these stresses to cancer phenotypes and the recent
efforts to develop therapeutic strategies targeting hypoxia
pathways, a detailed understanding of the mechanisms and
influences of these stresses in tumors will be of significant interest.
We have previously used gene signature approaches to estimate
the role of hypoxia [3] and lactic acidosis [8,25] in the
heterogeneity and clinical phenotypes of human cancer. The
hypoxia signature obtained in cultured cells exposed to hypoxia
allows the recognition of the molecular features common to
multiple cancer types – in turn permitting the identification of
patients with high clinical risks due to strong hypoxia response [3].
Additionally, linking prognostic molecular signatures of human
cancers to ex vivo experimental cell culture models provides a
relevant and controlled system that can be used in mechanistic
studies. Patients who are most likely to benefit from targeted
therapeutics can then be recognized by the high expression of the
hypoxia gene signatures. Therefore, substantial synergy and the
potential for novel biological insights can be obtained by
reciprocal flow of information between the in vitro and in vivo
systems. However, the basis for variation in the hypoxia and lactic
acidosis signatures in tumors is entirely unknown.
Due to increased proliferation and defective mechanisms for
monitoring genome integrity, one of the hallmarks of cancer is the
presence of with alterations of single nucleotides or CNAs with the
amplification/deletion of regions of chromosomes of various
lengths. These mutations and CNAs are likely to contribute to
the variations of the gene signatures of tumor microenvironmental
stresses. For example, it is known that HIF transcriptional
Author Summary
Gene signatures are a powerful tool to investigate
biological processes in human cancer. However, it is clear
that these gene signatures do not fully reflect the
complexity of human cancer. Here we demonstrate how
a latent factor model can improve the in vivo relevance of
these pathway-associated gene signatures by dissecting
them into co-regulated transcriptional components which
better represent the structure in human cancer. We use
this approach to analyze hypoxia and lactic acidosis gene
signatures to identify latent factors that represent distinct,
interacting components of the various biological processes
which are in the initial gene signatures but poorly
dissected. Some factors are clustered in small chromo-
somal regions and their expression values are highly
correlated with their DNA copy number in both cancer cell
lines and human tumors. Therefore, the gene dosage at
the DNA levels may explain the differences in gene
expression. Several factors contain genes which are known
to directly modulate the hypoxia response and allow us to
generate testable hypotheses regarding particular copy
number changes and hypoxia signatures. Therefore, the
use of latent factor analysis is a powerful means to identify
pathway-associated changes in the DNA copy number and
gene dosage.
Factor Models to Discover Sub-Signatures
PLoS Computational Biology | www.ploscompbiol.org 2 September 2010 | Volume 6 | Issue 9 | e1000920complexes and hypoxia pathways are constitutively activated in
the patients with von Hippel-Lindau disease, a genetic disease in
which the VHL gene is either inactivated or deleted [28]. In
addition, tumor microenvironmental stresses may also select
cancer cells with particular CNAs with strong metastasis
phenotypes and invasive behaviors [27,29,30]. It is therefore
interesting to identify CNAs associated with the hypoxia and lactic
acidosis pathways in human cancers.
In this study, we seek to use sparse latent factor analysis to
identify CNAs associated with the hypoxia and lactic acidosis
response in human cancers. The work that we present here is
based on the model described in [20], but should be repeatable
with any version of factor models. Specifically, we fit a latent factor
model of the gene signatures of hypoxia and lactic acidosis in one
data set of 251 breast tumors (Miller) from [20] to generate 56
latent factors. These factors then allow for connections to be made
between a numbers of different data sets, which can be used to
generate biological hypotheses regarding the basis for the variation
in the gene expression signatures of hypoxia and lactic acidosis.
We have identified variation in the expression of several factors on
the RNA level which are highly associated with CNAs in similar or
distinct chromosomal regions. Our findings lead to multiple, easily
testable hypotheses about some critical genes in relation to the
dyregulation of the hypoxia pathway in human cancers. Taken
together, these results suggest the possibility that tumor segmental
aneuploidy makes a significant contribution to the variation in the
hypoxia and lactic acidosis gene signatures seen in human cancers
and demonstrates that latent factor analysis is a powerful means to
uncover such a linkage.
Results
Identify the BAC clones associated with the hypoxia and
lactic acidosis gene signatures
Chromosomal aneuploidy and CNAs are known to lead to
changes in the RNA expression levels of genes in the correspond-
ing chromosomal regions and contributes to the altered gene
expression deregulation of myriad pathways during oncogenesis.
Given the potential contribution of the CNAs to variation in gene
expression, and the likely survival advantages (to the tumor cells)
under selection due to microenvironmental stresses, we seek to
identify the CNAs associated with the expression of hypoxia and
lactic acidosis gene signatures in tumors. In a previous study, the
gene expression of wound signatures was used to identify CNAs in
breast cancers as potential regulators of such gene expression
program [31]. We used similar approach to identify tumor CNAs
associated with the hypoxia/lactic acidosis gene signatures by
examining a breast cancer expression dataset (Chin) with both
gene expression and CNAs variations based on comparative
genomic hybridization (CGH) [32]. We projected the hypoxia and
lactic acidosis gene expression onto the Chin data set and
calculated the Pearson correlation against the measurements of
each of the 2150 BAC clones for these tumors (Figure 1). There
are some chromosomal locations that show associations between
the hypoxia and lactic acidosis signatures, such as 1p and 7p for
lactic acidosis and 1q, 5q and 13p for hypoxia. But we found no
statistically significant associations between signatures and CNAs
at any locations in the genome after using the strict alpha level of
0.01 after Bonferroni correction.
Use of human cancers to dissect the gene signatures into
multiple latent factors
The modest correlation between the BAC clones with the
hypoxia and lactic acidosis signatures may be due to the complex
composition of gene signatures in human tumors and other
confounding factors. In order to further dissect such complexity,
we used a latent factor model to break these signatures down based
on coherent expression in tumor tissue and to test for association
between components (sub-signatures) of the gene signatures and
CNAs. Factor analysis is becoming a standard technique for the
analysis of microarray expression data. In general, it is a simple
Figure 1. The association of BAC clones with the hypoxia and lactic acidosis gene signatures. The correlation between signature –
hypoxia (A) and lactic acidosis (B) - and copy number change in the breast cancer data set from Chin. The x-axis shows the location along the genome
of the different CGH clones, and the y-axis shows the level of association (2ln(p-value) of Pearson correlation). Dashed lines are drawn at alpha=.05
after Bonferroni correction for multiple testing (2150 tests, one for each CGH clone). We note that the signatures alone do not show strong
correlation with any particular genomic location, which makes it impossible to assess relationships between signatures and CNA without some way
to break up the signatures into smaller groups.
doi:10.1371/journal.pcbi.1000920.g001
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matricies. In our case, if X is a PxN-dimensional matrix of
expression values, then we write
X~ALze ð1Þ
A is called the factor loadings matrix (a matrix of regression
coefficients) and L is a matrix of factor scores (this may also contain
design vectors). Finally, e is the PxN-dimensional matrix of
idiosyncratic errors. We assume ei,j,N(0,si
2) which implies that
the corresponding PxP covariance matrix, which we label V,i s
diagonal with s
2
i in the i
th position. While this may seem restrictive,
it is exactly the covariance structure in X that is being described by
the latent factors, and therefore more complex covariance structure
in e would be redundant and potentially lead to issues with
identifiability. There are multiple versions latent factor models in
the published literature, including principal components [33], non-
negative matrix approximation [34], sparse latent factor models
[20] and partialleast squares [35]. We utilized the version from [20]
called Bayesian factor regression models (BFRM), but our general
approach can be applied using any version of factor modeling.
BFRM tries to make choices of A and L such that there are a large
number of zeros in the matrix A, thereby creating a parsimonious
model of the variation seen in X.
One of the key features of factor models is the ability to project
factors discovered in one data set onto another. This allows the
comparison of phenotypes across different data sets, such as
hypoxia linked to expression in one data set and CNA linked to
expression in another data set. In order to assess the relationship
between derived latent factors and interventions/variables from
other experiments, we need to be able to estimate L in a new data
set, given a previously discovered loadings matrix, A. This is a well
known problem of inverse regression and we will utilize the
approach described in [36]. We define Y to be a new set of
expression data, and suppose we wish to estimate the factor scores
on this data set, Ly. Then if A is the matrix of factor loadings
(regression coefficients) from model fitting and V is a diagonal
matrix containing the gene by gene variance estimators, we
compute
Ly~ IkzA0V{1A
   {1
A0V{1Y: ð2Þ
(In this equation, Ik is a k-dimensional identity matrix.) This allows
us to build a factor model on any data set and project those factors
onto any other data set in which we have measurements of all of
the relevant probe sets.
The ability to project factor models onto different data sets
allows the possibility of comparing new experimental data sets,
such as the hypoxia and lactic acidosis signature experiment, to
any of the thousands of publically available data sets with different
levels of information, including CNAs from array CGH. The
overall analysis scheme of our approach for the rest of the paper
is presented in Figure 2. We note that there is an important
assumption which is implicit in equation 2. We assume that the
factor loadings obtained from the analysis of the first data set are
valid for the analysis of the second data set. In the context of sparse
factor modeling, we know that genes that share non-zero loadings
for a specific factor also share elements of the expression pattern
described by that factor. The assumption that the loadings matrix
remains unchanged from data set to data set translates into the
assumption that genes which show co-expression in one data set
will continue to show co-expression in a new data set. It is evident
that the extent to which this will hold true is dependent on the
character of the two data sets in question. However, Figure 3 and
its accompanying analysis demonstrate that this paradigm may
hold true in a larger array of data sets than one might expect, such
as across different tumor types.
Because we are interested in the relationships between gene
expression and the tumor microenvironmental stresses, we
restricted our attention to a set of 2984 genes whose expression
were found to be affected under conditions of hypoxia and lactic
acidosis [25]. The matricies (A and L) that are derived in this
analysis, along with the parameter file used by BFRM, are
included in the statistical supplement (Text S1). Fitting the latent
factor model to these genes in a breast tumor expression dataset
(Miller) [37] of 251 tumors, we obtained 56 latent factors (genes in
each factors presented in supplementary Text S2). The expression
of these factors is largely coordinately expressed across tumors in
the Miller dataset, as exemplified for factor 26 in Figure 3A. In
addition, the relationship of these genes is mostly conserved in an
independent dataset of 118 breast tumors [32] (Figure 3B, labeled
as Gray dataset, p=2.2610
215). The estimation of the statistical
significance of coordinate expression in different tumor expression
data sets is discussed in the methods section. Although we don’t
expect coordinate gene expression to persist in other tumor types,
we find that coherent expression of the genes in factor 26 is also
preserved in lung (p=7.3610
28) and ovarian cancers
(p=7.6610
210) (Figure 3C, D) [1,38], but is largely lost in brain
cancers (p=.10) (Figure 3F) [39]. We find that this is generally the
rule, and not the exception, for most factors. Figures showing the
expression of the genes in all 56 latent factors in these five human
tumor datasets are included in the Figure S1.
Biological annotation of the latent factors in human
cancers
To further functionally annotate these coordinately expressed
genes in the discovered latent factors, we used a web-based
statistical tool Gather [40] to test whether the genes in each factor
are significantly enriched in Gene Ontology (GO) or chromosomal
locations. This analysis found that 30 latent factors are
significantly enriched in at least one GO (p,0.001). These
factor-enriched GO terms include glycolysis/gluconeogenesis
(factor 9), unfolding protein response (factor 10), neoplasm
metastasis (factor 15), TGF-b (factor 19) and immune response
(factor 6 and 16) (Table S1, Table S2, Table S3). Interestingly,
many of these biological processes have been previously shown to
be linked with hypoxia and/or lactic acidosis in many studies. For
example, hypoxia is known to trigger gene expression pathways
related to glycolysis as well as genes in the TGF-b pathway and
epithelial-mesenchymal transition [41–43]. Additionally, hypoxia
and acidosis are also known to trigger tumor metastasis [44,45]
and the ‘‘unfolding proteins response’’ [46–48]. The discovery of
factors representing these processes is encouraging and indicates
that factor analysis has the potential to uncover links between these
processes and the influence of hypoxia and lactic acidosis in
human cancers.
Statistics to evaluate chromosomal enrichment of genes
in factors – local enrichment ratio
In addition to enrichment for biological processes, gather
analysis indicates that 22 latent factors also exhibit significant
spatial basis with significant enrichment (p,0.001) in different
chromosomal locations (Table S1). Such spatial enrichment
suggests that events in these chromosomal regions may contribute
to their coordinated expression in tumors. We devised a separate
measurement and statistic, the local enrichment ratio (LER), to
Factor Models to Discover Sub-Signatures
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chromosomal association. Given a set of genes, the statistic is
based on the ratio of two distributions: 1) the distribution along the
genome of the genes in the set and 2) the distribution along the
genome of the collection of all possible genes that might have been
in the list. In our case, the gene subset will consist of genes in a
factor and the full list will consist of the 2984 genes from which we
built our factor model (detailed in the methods section).
This is a similar approach to that taken in KC-SMART [49] for
the analysis of CGH data with two key differences. First, we are
applying our approach to specific subsets of genes (each of our 56
factors) and testing the hypothesis that those subsets are enriched
for a particular location. This is in contrast to KC-SMART [49],
which is a general test designed to identify regions of CNA, and as
such is not directly applicable. Second, we are applying our model
to genes that have been grouped based on mRNA coexpression,
thus our test is performed completely independent of data on copy
number variation such as array CGH.
When we plot the calculated LER for the genes in each latent
factor along the 23 chromosomes, we observe prominent peaks
for several spatially-biased latent factors (Figure 4A, C, D) in
one or two chromosomal locations against the background of
noise in other locations. In contrast, factors without any
significant chromosomal enrichment produce broad, non-
specific peaks with low scores (Figure 4B). We find that the
g e n e si n1 8o u to ft h e5 6d i s c o v e r e df a c t o r se x h i b i tl o c a l
enrichment ratios of over 3 for particular chromosomal
locations (Table S1). This independent measurement of
chromosomal enrichment shows a high degree of agreement
with gather analysis. We do not have a theoretical distribution
for random draws of this ratio under conditions of no CNA.
However, simulation studies using random draws from the
2984 hypoxia/lactic acidosis genes, using a kernel standard
deviation of 5% of the length of the chromosome, suggests that
the probability of generating a maximum local enrichment
ratio over 3 across the whole genome, given the null hypothesis,
is less than 1610
24. Matlab code for computing the local
enrichment ratio is included in the statistical supplement (Text
S1). Figures showing LER for all 56 latent factors are included
i nt h eF i g u r eS 2 .W eh a v et e s t e dvarious window sizes and have
determined that these findings are relatively insensitive to
kernel width (Figure S3).
Figure 2. The flow chart of integrative genomic analysis. The flow chart shows the myriad data sets and data types that we integrate to
generate the use cases outlined in this section. All case studies utilize a set of 56 factors built with sparse latent factor models from the Miller breast
tumor data or the two signatures generated from the Chi data set. The red arrows represent the training of a model with a given data set. Green
arrows represent projection of a set of factors or signatures onto a new data set, and the black arrow represents a visualization technique (shown in
Figure 2). The fat gray arrows represent Pearson correlation calculations.
doi:10.1371/journal.pcbi.1000920.g002
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in tumors
The association of many factors with particular chromosomal
locations suggests that their co-variation in cancer gene
expression may be due to gene dosage caused by CNAs or other
spatially-biased gene regulations in those chromosomal regions.
To test these possibilities, we project our factors into a breast
cancer data set (Chin et al) [32] as well as breast tumor cell lines
(Neve et al) [50] both with both gene expression and CNA data.
The expression scores of the 56 latent factors were assessed on
both tumors samples and cancer cell lines. These were then
compared with the 2150 CGH clones in the corresponding tumor
and cell line samples using Pearson correlation. Plots showing the
strength of correlation for two of these factors are shown in
Figure 5. Although many factors show no particular association,
approximately 1/3 factors do show a significant degree of
association between factor expression and BAC clones in small
chromosomal regions in both tumors and cell lines. Using a
filtering criteria of minimum p-value less than .01 after
Bonferroni correction for 2150 hypothesis tests in both tumor
and cell line data sets, and requiring the genes defining the factor
to show a significant overabundance in the same chromosomal
region, we identified 17 factors both statistically and structurally
associated with CNA regions of different sizes (Figure 5A, B and
Figure S4). This high degree of association in both tumors and
cancer cell lines strongly suggests that these 17 factors are indeed
related to CNAs such as segmental aneuploidies. For example,
factor 26 is shown to be linked to CNA on chromosome 1 in
human tumors (Figure 5A) with the strongest association between
the factor and BAC clone RMC01P074 (Figure 5B). Similarly,
among breast cancer cell lines, the expression of factor 26 is
shown to be linked to CNAs on chromosome 1q (Figure 5C), with
the highest association with BAC clone RP11-57I17 (Figure 5D).
These results are entirely consistent with the results of enrichment
in 1q from the analysis using both Gather and LER. Taken
together, the variation in the expression of the genes comprising
factor 26 are highly associated with the gene dosages and
chromosome 1q CNA. Amplification of 1q has been previously
noted in breast cancer and is associated with important clinical
outcomes [32]. The re-discovery of this CNA associated with
factor 26 validates our approach. Another example is that the
expression of factor 30 is highly associated with segmental
aneuploidies in 8p21–23 in both tumors (Figure 5E, F) and
cancer cell lines (Figure 3G, H). It is interesting to note that many
genes in the factor 30 are known to be hypoxia-inducible (e.g.,
clusterin [51] and stanniocalcin 1 [52,53]) and may represent the
CNAs of HIF-1a target genes. Among the CNAs associated with
the 17 latent factors (included in Text S3), many have been
previously recognized as high copy amplification regions in the
original study of array CGH (Table S1). It is interesting that three
of these CNA-associated factors – 8q21–24 (factor 35), 17q21–25
(factor 5, 17), 20q13 (factor 46)—are also reported to be linked
with poor prognosis in another independent breast cancer study
using a spatial enrichment of gene expression [54].
Figure 3. The coordinated gene expression of latent factors in various human tumors. The expression of genes in the factor 26 in the Miller breast
cancer datasets from which the factor was first derived (panel A). Similar coordinated expression is also found for expression data of another breast cancers
(Gray - panel B), Lung (Nevins - panel C) and Ovarian (Burchurk - panel D) cancers. But such coordinated expression is not found in the brain (Frejie - panel D)
cancers. Ordering of the rows (bottom to top) is increasing in the loading of the first principal component in the Miller data set. This row order is retained in all
five heatmaps. Ordering of the columns (from left to right) is increasing in the first principal component. Thisi sr e c a l c u l a t e df o re a c hh e a tm a p .
doi:10.1371/journal.pcbi.1000920.g003
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latent factors may allow the recognition of CNAs with a higher
confidence due to their impact on gene expression than from the
mere use of BAC data or the examination of the spatial bias of
gene expression. Such an approach is especially of value in the
instances of low level of amplification and may explain the
confident identification of several new putative CNAs (Table S1).
Of these, 3q21–25 (factor 7) has been reported to be linked with
poor prognosis in breast cancers [54].
Several factors found to be enriched in chromosomal locations
based on the Gather and LER analysis did not show similar
significant correlation with CNAs in the tumors and cancer cell
datasets. This discrepancy may be due to the inconsistency
between different datasets or tumors from the cell lines or clustered
chromosomal locations in the same biological pathways show
clustered in chromosomal location.
Latent factors reflect potential trans-relationships
between CNAs and expression
Most of the factors are associated with the CNAs in the
chromosomal regions where the genes in the factors reside and
suggest that such variations in ‘‘cis’’ are due to the variations in
gene dosage caused by CNAs. We also detect a strong relationship
between the expression of both factor 12 and 16 with CNA in a
small region in the center of chromosome 12q in both tumors
(Figure 6A, D) and cancer cell lines (Figure 6B, E). In contrast to
the significant LER enrichments for other ‘‘cis-’’association factors
(Figure 4), the genes in these two factors show no spatial bias and
enrichment by either GATHER or LER (Figure 6C, F). Instead,
the genes in these two factors are scattered along various
chromosomes without significant clustering (Figure 6C, F). It is
not clear how the CNAs in particular chromosomal regions can
lead to the coordinated expression of genes in these two factors
without any chromosomal spatial bias. One possible explanation is
that factors 12 and 16 may represent instances of ‘‘trans’’-
regulation in which segmental aneuploidies leads to transcriptional
responses of these genes in the factors, instead of gene dosage
effects in most other factors. It is also relevant to point out that
factor 12-asscoated CNAs in 12q14–q15 has been noted to be
prominent in other tumors, such as liposarcomona [55], glioma
[56] and rhabdomyosarcoma[57]. This region contains HMGA2,
a well known factor involved in the transcriptional regulation of
Figure 4. The local enrichment ratios as measures of chromosomal enrichments of latent factors. Local enrichment ratios (y-axis) for the
genes in latent factor 7, 32, 23 and 26 (A,B,C and D respectively) along the 23 autosomes (X-axis). Chromosomes are colored alternately blue and
black for visualization. The red crosses designate the physical locations of the genes in the respective factor with vertical jitter added to allow
visualization. A local enrichment ratio over 5 is considered significant, therefore we conclude that factors 7, 23 and 26 demonstrate significant
enrichment for genes in specific chromosomal regions. While 32 demonstrates no local enrichment.
doi:10.1371/journal.pcbi.1000920.g004
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YEAST4, are critical to the p53 pathway. Although this is a
possible explanation, this possibility remains to be experimentally
tested.
Factor 26 as a predictor of low hypoxia response
In the sections below, we will present several examples of
biological hypotheses resulting from our analysis. It is important to
note that these hypotheses will still need to be validated. However,
it is the ability to generate hypotheses by bringing together
disparate data sets that represents the power and novelty of our
approach.
Given that these factors are identified from the hypoxia gene
signature, we examined the relationship between these factors and
the hypoxia gene signature. Such analysis identifies a significantly
negative relationship between factor 26 and the predicted hypoxia
pathways in both Miller and Chin breast cancer (Figure 7A, B)
[32,50]. These results suggest that a high level of expression of
factor 26 is associated with a lower level of hypoxia response. It is
interesting to note that the breast tumors labeled as 1q/16q CNA
based on cluster analysis of array CGH data in the Chin data have
a more favorable clinical outcome [32]. Given that a strong
hypoxia signature is associated with poor clinical outcome [3,25],
the link between 1q CNA and low hypoxia response is also
consistent with better clinical outcomes. Therefore, we postulate
that a high expression level of factor 26 in human cancer is
probably associated with 1q CNA and significantly negatively
associated with hypoxia pathways in human breast cancer
(Figure 7A, B).
Among the genes contained in the factor 26, there is one known
negative regulators of HIF-1a proteins – Egl Nine Homolog 1
(EGLN1 or PHD2). The high levels of EGLN1 are known to
suppress HIF-1a transcriptional activity [59] since it encodes a
protein that catalyzes the post-translational formation of 4-
hydroxyproline of the proline residues of HIF-1a and targets it
for degradation via the von Hippel-Lindau ubiquitylation
complex. Additionally, fumarate hydratase (FH) encodes a protein
that is an enzymatic component of the tricarboxylic acid (TCA)
cycle and its deactivating mutations lead to high level of HIF-1a
and tumor formation [60]. Thus, the high expression level of
EGLN1 (and maybe FH) in factor 26 due to local segmental
aneuploidy may contribute to lower HIF-1a activities. When the
HIF-1a protein level in the several breast cancer cell lines was
cultured under ambient air, we found that variation in HIF-1a
protein levels were inversely correlated with factor 26 expression
(p=0.0092) in a group of breast cancer cell lines [50] (Figure 7C–
E). This result is consistent with a previous study [61] showing that
MDA-MB-435S and MDA-MB-231 (with low level of factor 26)
having a high glycolytic phenotype with elevated HIF-1a protein
and glucose uptake. In contrast, MCF-7 has a relatively high factor
26 activity and is found to be lacking glycolytic phenotypes [61].
Taken together; these data suggest that CNAs in 1q leads to the
Figure 5. The association of mRNA gene expression and DNA copy numbers of latent factors. The degree of association (2log (p value)
of Pearson correlation, Y-axis) between the expression of factor 26 with the BAC clones along the 23 chromosomes (X-axis) in breast tumors, A, and
cancer cell lines, C, with the significant association with indicated BAC clones in 1q (panels B and D). Similar analysis has been performed for genes in
factor 23 in breast tumors (panels E and F) and cancer cell lines (panels G and H) with indicated BAC clones in 22q.
doi:10.1371/journal.pcbi.1000920.g005
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hypoxia pathway and aerobic glycolytic phenotypes. These results
highlight the potential of our approach to elucidate the
mechanisms underlying the hypoxia pathway and the aerobic
glycolytic phenotypes of human cancers.
Discussion
The role of DNA copy number alterations in the gene
expression
Cancer genome aneuploidies, characterized by mutations,
duplications and deletions, play an important role in oncogenesis.
Various microarray technologies have been used to perform
genome-wide investigations of copy-number changes through
array CGH [62,63] to identify many putative oncogenes and
tumor suppressor genes. These changes in DNA copy number or
gene dosage often lead directly to changes in expression levels of
the RNAs for the relevant genes (cis-covariations) or indirectly
other genes outside of DNA CNAs (potential trans-covariations).
These changes in gene expression may contribute to transforma-
tion and progression along with oncogenic processes. Therefore,
correlation between chromosomal abnormalities and gene expres-
sion levels may provide a powerful means to identify tumor
aneuploidies.
Although array CGH is a powerful tool for documenting DNA
copy number on the genomic landscape, the routine application of
array CGH to every tumor tissue used in gene expression studies is
not feasible. Theoretically, candidate segmental aneuploidy in
human cancers can be detected based on the spatial bias of gene
expression without the need for the actual array CGH microarray
data. For example, a previous study using gene expression to
identify segmental aneuploidy had identified MTDH as candidate
oncogene in 8q22 amplified (factor 35) in a small region in breast
cancers [54]. In addition, it is still challenging to identify
functionally relevant aneuploidy with confidence as well as the
insight into the biological mechanism and clinical relevance of
CNAs. In addition, these methods may identify only the cis-
covariations in which the variations in gene expression are
physically located on the chromosomal regions with segmental
aneuploidy. It will be difficult to identify trans-covariations as
Figure 6. The association distant DNA copy numbers with the gene expression two latent factors. The degree of association in p value
(Y-axis) is plotted between the expression of factor 12 with the BAC clones along the 23 autosomes (X-axis) in the breast tumors, A, and cancer cell
lines, B, with the significant association with indicated BAC clones in 12q. Similar figures for factor 16 are shown in D and E. The red crosses in C and F
designate the physical locations of the genes in latent factor 12 along the 23 autosomes (X-axis) with the degree of spatial enrichment (LDR) shown
as a density ratio (Y-axis).
doi:10.1371/journal.pcbi.1000920.g006
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wound signature [31].
Our study, presented in this manuscript, presents a novel
approach – the use of sparse factor analysis to identify CNAs in
human cancers which are associated with biological processes as
captured in the in vitro derived gene signatures. We reason that the
CNAs may lead to the coordinated expression of genes within
these (cis-covariations) or other distant chromosomal regions (trans-
covariations), and thus identifiable as factor components across
different human cancer datasets. Since this method is initiated by
pathway-specific gene signatures, which can later be linked to
latent factors and then CNAs in specific chromosomal regions with
high confidence, the discovered association can better enable us to
gain biological insights into these pathway-associated CNAs to
enable better development of hypotheses in terms of the causes
and consequences. Finally, the overall approach provides a generic
framework for the joint analysis of disparate data sets and for the
generation of hypotheses based on data collected at many different
experimental systems and in various biological contexts.
The advantages and limitations of factor analysis to
discover CNAs in human cancers
In the effort to identify the CNAs from array CGH data, it is
sometimes difficult to draw the most appropriate filtering criteria.
This issue is especially exacerbated by the issue of variations in the
degree of DNA aneuploidies among different tumors and cancer
cells, the contaminating normal cells and the differing spatial
resolution for the microarray formats for array CGH. For
example, the large sizes of the BAC clones make it especially
challenging to distinguish authentic signals from noise. Our
alternative approach, starting from gene expression data, is likely
to identify those CNAs which are functionally relevant in terms of
significant variation in gene expression. For example, many
segmental DNA aneuploidies found in our analysis may not have
been previously recognized with confidence due to their modest
and inconsistent deviation from the array CGH. But their
variations have led to significant and consistent changes in the
expression of the genes which allows their confident recognition
using our approach. Thus, latent factors may present an
Figure 7. The inverse relationship of factor 26 with the hypoxia response and HIF-1a protein levels. The degree of the association
between factor 26 (Y-axis) and hypoxia gene signature (X-axis) is shown for the Miller, A, and Chin, B, breast cancer dataset. Panel C shows the level of
HIF-1a proteins under ambient air of various indicated breast cancer cell lines are determined by Western blots. These cells are shorted based on the
normalized level of HIF-1a protein and correlate with the expression level of factor 26 (panels D and E).
doi:10.1371/journal.pcbi.1000920.g007
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aneuploidies which are associated with particular biological
processes.
Since this approach focuses on gene expression, the identified
segmental aneuploidies may agree or disagree with the quantita-
tive analysis from the measurement of DNA copy number. For
example, our approach has identified many high copy amplifica-
tion regions found in the original study of array CGH in breast
cancers. However, in addition we have identified several
additional CNAs with confidence. The identification of these
factors from the latent factor model indicate that our approach
may help to incorporate coordinated gene expression patterns
which leads to a higher confidence in the interpretation of CNA
than that derived from the use of BAC data alone or the
incorporation of gene expression data from single genes. This is
especially of value in instances of low level amplification. There
are also several CNAs which we did not discover through our
factor analysis, such as the recurrent CNA in 11q13, 21q22 and
17q12. This may be due to the fact some of these CNAs do not
lead to significant gene expression in the factors or their effects on
the gene expression are not significantly correlated with the
hypoxia or lactic acidosis.
Examples for the improved understanding from the
factor analysis of gene signatures
The use of factor analysis to dissect the original gene signatures
has shown its utility in several biological contexts. The combination
of signature-derived latent factors has been shown to improve the
prognostic value and predictive power of the original hypoxia and
lactic acidosis signatures [26]. A recent analysis of the prognostic
factors in breast cancer has highlighted the importance of a
glycolytic enzyme PGK1 and tumor glycolysis in the prognostic
value of stress signatures [64]. In addition, factor analysis has
allowedthe moleculardissectionoftheRaspathwaysinto individual
components [14]. In this study, we have further identified the
potential role of 1q CNA in the degree of hypoxia response in the
breast cancers. This finding has suggested a role of the gene dosage
of two HIF-1a negative regulators (ELGN1and FH) as determinant
of tumor hypoxia responses as discussed below.
The link of CNAs to the variations in hypoxia/lactic
acidosis response in human cancers
There are three reasonable possibilities; variation in the hypoxia
response program might reflect: (1) actual variations in oxygen
tension in the tumors; (2) cell type-specific variations in the
magnitude of, or threshold for, the response to bona fide hypoxia,
similar to those seen in our analysis of different normal cells; or (3)
inappropriate activation of the hypoxia response resulting from
genetic and/or epigenetic alterations in cancers. Although the
hypoxia response in tumors is usually thought to be caused by the
first mechanism, evidence suggests contributions from the second
and third mechanisms as well. For example, activation of the
hypoxia response program in clear-cell RCC is almost certainly
caused by loss of VHL [4] rather than by low oxygen tension. In
breast cancer, the over-representation of p53 loss-of-function
mutations in the tumors with elevated hypoxia responses suggests
that the loss of the p53’s role in inhibiting HIF-1a protein stability
and hypoxia-induced cell death [4,55–57] may be a factor in these
tumors. Other oncogenic alterations in regulatory systems [3–7]
might also play a role in triggering or modifying the hypoxia
response in human cancers; a dissection of the contributions of
tumor oxygen levels and disordered regulation of the hypoxia
response in individual tumors will, therefore, be important in
developing therapeutic strategies based on exploitation or
inhibition of this program. Our results clearly demonstrate that
a significant amount of tumor CNAs are associated with the
hypoxia and lactic acidosis responses in human cancers and these
CNAs may contribute to variations in the hypoxia and lactic
acidosis gene sigantures. For example, the amplification of 1q
(factor 26) is often observed in subsets of breast cancers and is
associated with a group of breast cancers with more favorable
clinical outcomes [32]. The identification of negative correlation
between factor 26 (1q CNA) and the hypoxia response in breast
tumor and cell lines may help to explain such observations. Our
analysis has pointed out additional associated relationship between
particular CNAs and the hypoxia/lactic acidosis signatures to
allow the development of hypothesis on the mechanistic basis for
such association for experimental validation.
Tumor microenvironmental stresses as selection pressure
for CNAs
It is possible that the hypoxia, lactic acidosis and other tumor
microenvironmental stresses play a direct role in selecting for the
cancer cells with particular CNA. Such concepts have been
suggested by many reviews on the ability of hypoxia and acidosis
to select for tumor cells with strong metastasis phenotypes and
invasive behaviors [27,29,30]. Many of the breast tumor CNAs
observed in the Chin studies are also found in the cultured cells
undergoing telomere crisis and immortalization [32]. These
possibilities are also suggested by the CNAs we have identified
to be associated with hypoxia and lactic acidosis. For example we
have identified a strong positive correlation between the CNA in
22q11–13 associated with factor 23. Among the genes in this CNA
region is ATF4, a master regulator of transcriptional response of
unfolding protein response (UPR). It is known that hypoxia stresses
lead to the UPR and that the proper transcriptional module of
UPR is essential for cellular survival under hypoxia [65,66]. We
hypothesize that amplification of ATF4 and adjacent regions leads
to constitutive and strong UPR, conferring a survival advantage
for cells under hypoxia stresses.
Future direction and perspective
The strategy presented in this paper will be developed for
multiple sets of factors generated across the range of biological
pathways resulting from other microenvironmental stresses and
oncogenic signaling events. Further, the availability of both
sequencing data and gene expression data for sets of human
cancers from the Cancer Genomics Atlas Project will allow further
exploration of genetic changes identified as linked to dysregulated
expression of these gene signatures in human cancers. In one
sense, the dysregulated gene expression can be used as a biological
phenotype to help interpret and decipher the consequences of
genetic changes of different sizes, either on the amplification/
deletions of chromosomal regions of varying sizes or single base
mutations in human cancers. Such an integrative genomic
approach is likely to help unravel the enormous complexity of
human cancers and allow more precise and personalized
therapeutic strategies.
Methods
Statistical model specification
In general, for experiments performed on clones under strictly
controlled conditions, such as that, our models utilize multivariate
regression and analysis of variance with a fixed known design to
describe observed expression patterns. Suppose that we have p
isotope groups and n samples. We define X to be the p6n matrix of
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with elements hj,I, whose columns consist of the r known design
vectors. We model the measured expression values as:
xg,i~mgz
X
r
j~1bg,jhj,izng,i where ng,i are iid N0 ,yg
  
or, in matrix form,
X*N m10zBH,Y ðÞ
where 1’ is the n-dimensional column vector of 1’s and
Y=diag(y1:g).
Depending on the experimental context, the rows of H may
include entries reflecting treatment effects, environmental inter-
ventions, or clinical variables for which we want to control.
Sparsity priors
Because we are dealing with very high dimensional genomic
assays, we expect that most genes (probe sets) will not show
differential expression in relation to a particular design vector.
Mathematically, this statement is equivalent to the assumption that
the matrix B will be sparse (for most i and g we will have bg,i=0).
We reflect this assumption with the standard point mass mixture
distribution on the coefficients bg,i:
bg,i* 1{pj
  
d0 bg,i
  
zpjN bg,iD0,tj
  
Our assumption is that the probability of any particular probe
associating with a given design vector is quite low, so we assign p a
low mean Beta prior. This structure leads to models for intensity
values that are as parsimonious as possible while still identifying
isotope groups that are related to the design vectors.
Latent factors
We have previously performed genomic analysis of Human
Mammary Epithelial Cells (HMEC) which have been exposed to
lactate, acidosis and combined lactic acidosis for 24 hours (GEO
accession number GSE9649) [25]. We fit the sparse regression
model described above to this data, and from this analysis, we
selected a set of 2984 genes based on the posterior probability of
differential expression – the posterior distribution for p – for any of
experimental groups being greater than .99.
The latent factors model as described thus far assumes that all
sources of variation in intensity are known and represented by a
fixed design. An important feature of the modeling formulation is
the ability to account for unknown sources of variation such as the
activity of various biological pathways. These sources would be
reflected in common intensity patterns across multiple subsets of
isotope groups, and will be described by the identification of
various factors.
Extending the model to include factors can be expressed as
X*N m10zBHzAL,Y ðÞ
Where the k6n matrix L represents the realized values of k latent
factors across the n samples, having elements lj,i for factor j=1:k
on sample i=1:n. L is an analogue to the known matrix H (though
it contains unknown vectors to be learned). The columns of the
p6k factor loadings matrix A=ag,j are the coefficients of isotope
groups on factors (these are analogous to regression coefficients
in B.
We again make use of sparsity priors for the elements of A (the
same as those used for b). The elements of L may be given
standard normal prior distributions. The properties of this model
have been fully laid out fully in [3] along with details of
implementing the Markov Chain Monte Carlo (MCMC) algo-
rithm for fitting the parameters. Details on the use of this model in
the setting of predicting factor scores and pathway activity are laid
out in [1]. We make use of software which implements the MCMC
algorithm of [3] and is freely available to the public. The details of
using this software are described in [2].
We fit this factor model to the 251 samples from the Miller data
set and the 2984 genes from [25], resulting in the 56 factors that
we have described herein.
Enrichment in gene ontology and chromosomal
locations among the factors genes
Gather is a fully developed software product described [40]. To
assess enrichment for specific lists of probe sets, we simply drop the
list into the web based interface and all associations are tested and
reported.
Local enrichment ratio
We note that one of the features of the Bayesian sparse latent
factor model that we use is the estimation of posterior probabilities
for each gene and each factor, p*g,j. This parameter is interpreted
to be the posterior probability that gene g influences factor j or
alternatively the posterior probability that factor j is important for
describing the variation observed across samples for gene g. Now,
given a list of posterior probabilities for factor j we are faced with
the challenge of assessing the extent to which the genes with high
posterior probability cluster in a specific region of the genome. We
treat each factor independently, therefore for the purposes of
reducing notational complexity, we will drop the factor index, j.
Define xg to be the start location of a gene observed to be in the
factor and let kg(t) be a kernel function associated with genome
location xg. Because we know that CNA can occur across regions
of the genome that are relatively large compared to the length of a
gene, we approximate gene location with a point mass at its start
site. Using this approximation, we define kh(t) to be a discretized
normal distribution with mean h and variance t
2, truncated at the
edge of the chromosome on which h resides and properly scaled (to
add to 1). This function serves to distribute a gene observed to be
in the factor across a large set of locations across the genome.
We define the local enrichment ratio at a point t along the
genome as
g t ðÞ ~ 1=M
X
gpg kg t ðÞ
hi
,
1=M0
X
gkg t ðÞ
hi
Where M and M0 are integration constants, such that
M=gggtpg
*kg(t) and M0=gggtkg(t). This is a ratio of kernel
smoothed empirical distributions similar to that developed in [49]
and many other places. Kernel smoothers have a long history,
including their use in likelihood ratio tests. Some theory on the
properties of the ratios of kernel smoothed empirical distributions
has been worked out in [67] and their use in the context of partial
linear regression is described in [68]. However, literature on their
use in the context of gene expression data is minimal and their
application to posterior latent factor inclusion probabilities is
novel. For the purposes of this analysis, we are analyzing a set of
2984 genes, and this will limit our resolution to regions that are
significantly larger than the length of a gene. In general, the
appropriate kernel width (t
2) will depend on the number of genes
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smaller sandard deviation in the kernel). For this paper, we utilize
a standard deviation of approximately 5% of the length of a
chromosome. However, testing across a wide range of sizes
demonstrates a relative insensitivity to this parameter (Figure S3).
In order to estimate an appropriate significance level for the
local enrichment ratio for a particular factor, we simulate from the
null distribution by permuting the posterior probabilities. Thus, if
s(g) is a permutation, then a sample LER from the null hypothesis
is generated as follows:
g t ðÞ ~ 1=M
X
gps g ðÞ
 kg t ðÞ
hi
,
1=M0
X
gkg t ðÞ
hi
Repeated simulations, using multiple different permutations across
all factors demonstrates that a significant LER varies according to
the window size of the kernel. However, at a kernel width that is
5% the size of a chromosome, the probability of a maximum
LER.3 across the entire genome is less than 1/10,000. Similar
significance levels for kernel widths of .5%, 2%, 8% and 11% are
2.3, 2.6, 4.5 and 6.
The projections of factors into other datasets to
investigate relationship with CNA
In order to assess the relationship between derived latent factors
and interventions/variables from other experiments, we need to be
able to estimate L, given A, in new data sets. That is, we have a new
data set, Y, and we wish to estimate the factor scores on this data set,
Ly. This is a well known problem of inverse regression; however,
because we are in the situation of very high dimensional data, we
know that A’A will not be invertible. This means that we cannot
simply apply the least squares estimator, Ly=(A’V
21A)
21A’V Y.W e
address this issue by utilizing a Bayesian framework for the
estimation of Ly. In particular, we use the prior distribution
pL y
  
!exp {1=2 L0L fg
Thisis a simplified version of a more generalpriordescribed in [36].
Then if A is the matrix of factor loadings (regression coefficients)
from model fitting and V is a diagonal matrix containing variances
for each gene, we estimate
Ly~ IkzA0V{1A
   {1
A0V{1Y: ð2Þ
(In this equation, Ik is a k-dimensional identity matrix.) The
derivation of this posterior from the prior and likelihood are
discussed in both [36] and [69]. Goldstein et al. also discusses the
relationship of this estimator to ridge regression estimators [69].
The use of this solution to the inverse regression problem allows
us to build a factor model on any data set and project those factors
onto any other data set in which we have measurements of all of
the relevant probe sets. To test association between factors and
CGH, we project the factors discovered in [37] onto the data sets
from [32] and [50]. We then compare the 56 factor vectors to the
BAC clones from these data sets using Pearson correlation. This is
the same approach taken to project our factors onto the cell line
data from [25].
Estimation of the statistical significance of conserved
coordinate expression
We are interested in estimating whether a particular collection
of genes, showing coexpression in one data set, shows the same
type of coexpression patterns in a new data set. In essence, we
want to quantify the level of similarity between Figure 3A and
Figures 3B, C, D and E. It is first important to understand how
these figures were generated.
Note that, in this context, neither samples nor genes have a
canonical order, thus we may reorder both the rows and columns
of these heatmaps in order to make coherent expression more
clear. Thus, for visualization, we compute the first principal
component, u1, of the data matrix. Define rj to be the correlation
between u1 and row j of the data matrix and r to be the vector of
those correlations. Define |r|
+ to be the number of rows, j, in the
data matrix for which rj.0 and |r|
2 to be the number of rows
for which rj,0. We choose the sign of u1 so that |r|
+.|r|
2. The
columns are then sorted so that u1 is decreasing and the rows are
sorted so that r is decreasing.
One of the challenges inherent in assessing the extent to which a
particular expression pattern is conserved is due to the fact that the
samples are completely different. We note that the procedure
outlined in the previous paragraph can be used to sort a collection
of genes based on coexpression, and that it is entirely internal to
the data matrix. Thus, given a fixed set of genes and two
completely independent samples, we may use each data set to
perform this sorting. The rows of the five data matricies depicted
Figure 3 are all sorted according rmiller in order to enhance
interpretability.
We test the significance of conserved coordinate expression by
computing the Kendall correlation of two different methods of
sorting. Thus, from Figure 3, the Kendall correlation of rmiller and
rgray is .67, and the p-value associated with this correlation is
2.2610
215. Note that, by default, the computation of the Kendall
correlation statistic involves first replacing the elements of rmiller
and rgray with their ranks. Thus, this is a non-parametric, rank
based correlation. Scatterplots of the ranks, comparing Miller to
each of Gray, Nevins, Berchuck and Freije are shown in Figure S5.
The relationship between the factor expression and
hypoxia and lactic acidosis signatures
This equation described above is used to project both signatures
and factors – using B instead of A in the case of signatures. Thus to
assess both signature and factor expression levels on an n-
dimensional data set, one first projects the relevant factors and
signatures, then compares the obtained n-dimensional vectors to
each other with whatever test is relevant. In this paper, we use
Pearson correlation to assess significance of association. The
procedure for comparing signatures to array CGH is, thus, exactly
analogous to that used for comparing factors to array CGH.
HIF-1a proteins and association with factor 26
The indicated breast cancer cell lines were cultured under
ambient air, lysed and supplemented with protease inhibitor
cocktail (Roche Applied Science) followed by sonication and cold
centrifugation. Equal volumes of sample buffer were added to
20 ug of proteins, boiled, resolved on a 10% Tris-HCl gel (Bio-
Rad), and transferred onto polyvinylidene fluoride (PVDF)
membrane (Hybond-P, GE Healthcare). HIF-1a protein was
detected using anti-HIF-1a monoclonal antibody (cell signaling)
followed by horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG antibody (Abcam). The western blot was then
visualized by enhanced chemoluminoscence (Western Lightning-
ECL Plus, PerkinElmer) and exposure to film. Images were
digitized by scanner. To control for protein loading, the
membranes were stripped (Restore Plus, Thermo Scientific) and
reprobed with goat anti-rabbit antibody to beta-tubulin (Abcam).
Densitometric measurements were performed with ImageJ
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normalized HIF-1a with tubulin signals with factor 26 was
calculated by GraphPAD Prisms.
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Figure S4 The association of the BAC clones with the
expression of CNA-associated factors.
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Figure S5 Scatterplots comparing the ranking of genes in factor
26 as computed with each of the 5 different data sets. High levels
of correlation indicate a factor that is conserved between the two
data sets.
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Table S1 The gather analysis of the GO enrichments and
enrichment for all in their chromosomal locations based on gather,
local enrichment ratio (LER) and association with BAC clones for
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